ABOUT US

Meet the Visionary Team Behind Psycheceutical

OUR GOAL

Psycheceutical’s patented drug delivery technologies will significantly advance the medical application of psychedelic compounds by bringing the highest levels of safety and efficacy to this new class of medications.

Meet The Team

FDA Drug Development Veterans

Our visionary team of industry experts has 100+ years of combined experience in psychedelics, biotechnology, and business development across the pharmaceutical industry.

Savvy Technologists and Mental Health Science Experts

Our visionary founders are considered among the top minds in the psychedelic space, embracing the latest technologies to further the advancement of mental health science.

State-of-the-Art Biotech Solutions

Our groundbreaking Janus particle solution and NeuroDirect™ delivery system allow psychedelic compounds to be administered without unwanted side effects and toxicity.

Leadership

Click to read each team member’s bio

Zappy Zapolin

Chief Visionary Officer

Chad Harman

Chief Executive Officer

Dr. Anish Tuteja

Chief Science Officer

Michael Hlavsa

Chief Financial Officer
Kaia Roman

Kaia Roman

VP, Strategy & Communications

Advisory Team

Michael Gurin

Board Member
Dr. John Kutzko

Dr. John Kutzko

Formulations Advisor

Dr. Paul Waymack

FDA Regulatory Adviser
Dr. Ronald Aung-Din

Dr. Ronald Aung-Din

Clinical Advisor
Dr. Zachary Clayton

Dr. Zachary Clayton

Research Advisor

Dan Yerace

Strategic Adviser

Strategic Partners

A catalyst for developing therapies that improve outcomes, Coeptis accelerates commercialization opportunities by creating valuable partnerships with companies focused on quality, value, and innovation.

The experienced Coeptis team of healthcare professionals seek unique opportunities to improve outcomes for patients.

Dave Mehalick

Co-Founder & CEO

Christine Sheehy

Co-Founder, SVP of Operations, CFO

Gary Conte

SVP of Sales and Marketing